New Partnership to Advance Artificial Intelligence in Ophthalmology

The American College of Radiology® Data Science Institute® (ACR DSI) and the American Academy of Ophthalmology today announced a collaboration that will expand ACR DSI’s groundbreaking AI-LAB™ platform to include eye care.

Leveraging use cases and data from the Academy, this collaboration will accelerate the use of machine learning in the ophthalmic industry to the benefit of patients across the globe. 

“We’ve now made it easier for the ophthalmology community to access real-world examples for our own use cases. By working together with ACR, we are leveraging a platform developed for the radiology community to educate our own community about AI development and encouraging new AI to be developed that will benefit our specialty,” said Tamara R. Fountain, MD, president of the American Academy of Ophthalmology.

The Academy will provide the ophthalmology content and the ACR will provide the IT infrastructure to integrate the use cases and datasets into the landmark AI-LAB. This enables developers to build algorithms that include defined data elements and images useful for training and testing models. The Academy’s Committee on Artificial Intelligence, chaired by J. Pete Campbell, MD, MPH is leading this initiative.  

“This is another vital step toward making the groundbreaking AI-LAB platform the central hub for medical artificial intelligence algorithm development,” said Bibb Allen, Jr., MD, FACR, chief medical officer of the ACR DSI. “By sharing the AI-LAB as a resource for other medical communities, the ACR DSI supports efficient development of AI algorithms that can advance modern patient care.”

The ACR DSI made the initial version of the AI development framework available in April 2019. Get more information on ACR AI-LAB at ailab.acr.org.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version